SCHEMBL5505407

SCHEMBL5505407

O=C1CNCCN1I

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27046422 0.78
SCHEMBL2996473 0.72
SCHEMBL1866794 0.72
SCHEMBL40177 0.70
SCHEMBL17802439 0.70
SCHEMBL1866796 0.70
SCHEMBL28369190 0.70
SCHEMBL1254767 0.70
SCHEMBL3825082 0.70
SCHEMBL2678986 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223761-A1 QUINAZOLINE COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-08-09 EP disclosed
WO-2022125925-A1 COMPOSITIONS FOR TREATING DRY AGE-RELATED MACULAR DEGENERATION (AMD) COGNITION THERAPEUTICS, INC. (US) 2022-06-16 WO disclosed
WO-2019057053-A1 FUSED RING DERIVATIVE USED AS FGFR4 INHIBITOR 北京加科思益新药研发有限公司 2019-03-28 WO disclosed
EP-2853265-B1 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha AERPIO THERAPEUTICS INC (US) 2017-07-26 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-7435735-B2 Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors MERCK & CO., INC. (US) 2008-10-14 US disclosed
EP-1861376-A1 CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS F. Hoffmann-Roche AG (CH) 2007-12-05 EP disclosed
WO-2006097261-A1 CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-21 WO disclosed